Last reviewed · How we verify
Carbamazepine-Controlled Release
Carbamazepine is an anticonvulsant that stabilizes neuronal membranes by blocking sodium channels, reducing repetitive neuronal firing and propagation of seizure activity.
Carbamazepine is an anticonvulsant that stabilizes neuronal membranes by blocking sodium channels, reducing repetitive neuronal firing and propagation of seizure activity. Used for Epilepsy / seizure disorders, Trigeminal neuralgia, Bipolar disorder.
At a glance
| Generic name | Carbamazepine-Controlled Release |
|---|---|
| Also known as | Tegretol® Retard Tablets 200 mg |
| Sponsor | UCB BIOSCIENCES GmbH |
| Drug class | Anticonvulsant / Antiepileptic agent |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Carbamazepine acts primarily as a voltage-gated sodium channel blocker, which decreases the influx of sodium ions into neurons and stabilizes the inactive state of the channel. This mechanism reduces the frequency of action potentials and prevents the spread of abnormal electrical activity in the brain. The controlled-release formulation extends drug delivery over time, providing more stable plasma concentrations and potentially improved tolerability compared to immediate-release formulations.
Approved indications
- Epilepsy / seizure disorders
- Trigeminal neuralgia
- Bipolar disorder
Common side effects
- Dizziness
- Ataxia
- Diplopia
- Nausea
- Rash
- Hyponatremia
- Agranulocytosis
Key clinical trials
- Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older (PHASE3)
- Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older (PHASE3)
- Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures (PHASE3)
- Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures (PHASE3)
- Levetiracetam Versus Standard Antiepileptic Drugs (Carbamazepine and Valproate) Used as Monotherapy in Patients With Newly Diagnosed Epilepsy (PHASE3)
- The Effects on Cognitive Function of Levetiracetam (Keppra®) Compared to Carbamazepine (Tegretol®, Carmazepine®) as Monotherapy for Children With Partial Seizure; A Multicentric Randomized Controlled Study (PHASE4)
- Fed Bioequivalence Study of CBZ Formulations (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |